Um
Advancing Vaccine Science with Synthetic Precision
STR Technologies is a manufacturer of synthetic vaccine adjuvants for the global pharmaceutical and biotech industry. We partner with research institutions and commercial vaccine developers to deliver rigorously characterized adjuvant materials — on specification, on time, and at scale.
Our manufacturing platform combines precision chemistry with rigorous quality systems, enabling scientific teams to advance from discovery through late-stage clinical development with confidence in every batch.
Why Synthetic Adjuvants?
Synthetic adjuvants represent a fundamental shift in how the vaccine industry approaches immune potentiation — one driven by science, not supply chain compromise.
Purity and Consistency
Biological extraction introduces inherent variability. Animal-derived materials carry batch-to-batch inconsistency rooted in the organism itself — diet, health, seasonal biology. Synthetic manufacturing eliminates that variable entirely. Every lot of STR adjuvant is produced from defined chemical precursors under controlled conditions. The result is a product where specification is the starting point, not a distribution to manage.
Supply Chain Reliability
Natural-derived adjuvants carry sourcing risk by design. Seasonal availability, animal welfare regulations, and geopolitical supply pressures create uncertainty that compounds as programs scale. Synthetic adjuvants have no biological sourcing dependency. STR can guarantee availability at any scale, any time of year, regardless of external supply conditions.
Regulatory Clarity
Well-defined chemical entities simplify every stage of regulatory interaction. Analytical characterization is deterministic. Stability studies are interpretable. Filings with FDA, EMA, and NMPA are built on a documented chemistry — not a biological matrix that requires extensive comparative lot release testing. Synthetic is the path of least resistance through the regulatory landscape.
Our Capabilities
STR Technologies operates a purpose-built synthetic adjuvant manufacturing facility designed to support programs from early research quantities through commercial supply:
- Synthetic Manufacturing — synthesis, formulation, and fill operations under controlled conditions; full batch documentation and release testing
- Analytical Testing — structural confirmation (NMR, HPLC, MS), purity characterization, endotoxin testing, particle size analysis
- Regulatory Documentation — Drug Master File (DMF) support for FDA, NMPA, and EMA submissions; letter of access for IND/CTA filings
- Custom Formulation — adjuvant system development and formulation optimization for specific antigen platforms and route-of-administration requirements